Hostname: page-component-788cddb947-jbkpb Total loading time: 0 Render date: 2024-10-13T23:51:18.544Z Has data issue: false hasContentIssue false
  • English
  • Français

Deprenyl: The Exciting Possibility of Protective Effect

Published online by Cambridge University Press:  18 September 2015

J. David Grimes
J. David Grimes*
Affiliation:
Division of Neurology and Loeb Medical Research Institute, Ottawa Civic Hospital, University of Ottawa, Ottawa
*
Division of Neurology and Loeb Medical Research Institute, Ottawa Civic Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ontario, Canada KIY 4E9
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Focus on Parkinson's Disease
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue 1 , February 1991 , pp. 85 - 86
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

1.Parkinson Study Group. Datatop: A multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989; 46: 1052–1060.CrossRefGoogle Scholar
2.Grimes, JD, Hassan, MN, Thakar, J.Antioxidant therapy in Parkinson’s disease. Can J Neurol Sci 1987; 14: 483–487.CrossRefGoogle ScholarPubMed
3.Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
4.Landau, WM. Pyramid sale in the bucket shop: Datatop bottoms out. Neurology 1990; 40: 1337–1339.CrossRefGoogle ScholarPubMed
5.Csanda, E, Tarczy, M.Selegiline in the early late phases of Parkinson’s disease. J Neural Transm 1987; 25: 105–113.Google ScholarPubMed
6.Elizan, TS, Yahr, MD, Moros, DA, et al. Selegiline use to prevent progression of Parkinson’s disease. Arch Neurol 1989; 46: 1275–1279.CrossRefGoogle ScholarPubMed
7.Myllyla, VV, Sotaniemi, KA, Tuominen, J, et al. Selegiline as primary treatment in early phase Parkinson’s disease – an interim report. Acta Neurol Scand 1989; 126: 177–182.CrossRefGoogle ScholarPubMed
8.Teravainen, H.Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333–336.CrossRefGoogle ScholarPubMed
9.Tetrad, JW, Langston, JW.The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.CrossRefGoogle Scholar
10.Knoll, J.Deprenyl (selegiline): the history of the its development and pharmacological action. Acta Neurol Scand 1983; 95: 57–80.CrossRefGoogle ScholarPubMed
11.Diamond, SG, Markham, CH, Treciokas, LJ.Double-blind trial of pergolide in Parkinson’s disease. Neurology 1985; 35: 291–295.CrossRefGoogle Scholar
12.Quinn, NP.Anti-parkinsonian drugs today. Drugs 1984; 28: 236–262.CrossRefGoogle ScholarPubMed
13.Stern, GM, Lees, AJ, Hardie, RJ, et al. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson’s disease. Acta Neurol Scand 1983; 95: 113–116.CrossRefGoogle ScholarPubMed
14.Mann, JJ, Fox-Aarons, S, Wilner, PJ, et al. A controlled study of anti-depressant efficacy and side effects of (–) –Deprenyl. Arch Gen Psychiatry 1989; 46: 45–50.CrossRefGoogle Scholar